Nifty 17026.45 (-2.91%)
Sensex 57107.15 (-2.87%)
Nifty Bank 36025.5 (-3.58%)
Nifty IT 34606.1 (-1.97%)
Nifty Financial Services 17614.7 (-3.56%)
Adani Ports 717.15 (-5.94%)
Asian Paints 3143.10 (-0.04%)
Axis Bank 661.75 (-2.67%)
B P C L 376.85 (-5.81%)
Bajaj Auto 3334.60 (-1.68%)
Bajaj Finance 6807.05 (-4.47%)
Bajaj Finserv 16682.55 (-3.95%)
Bharti Airtel 738.75 (-3.45%)
Britannia Inds. 3555.30 (-0.51%)
Cipla 966.70 (7.42%)
Coal India 155.90 (-1.67%)
Divis Lab. 4937.80 (2.88%)
Dr Reddys Labs 4750.90 (3.47%)
Eicher Motors 2433.90 (-3.43%)
Grasim Inds 1690.10 (-4.34%)
H D F C 2741.70 (-4.40%)
HCL Technologies 1110.05 (-1.31%)
HDFC Bank 1489.90 (-2.36%)
HDFC Life Insur. 670.65 (-2.64%)
Hero Motocorp 2529.40 (-2.52%)
Hind. Unilever 2335.10 (-0.59%)
Hindalco Inds. 417.00 (-6.72%)
I O C L 120.95 (-3.74%)
ICICI Bank 722.20 (-3.84%)
IndusInd Bank 901.80 (-5.99%)
Infosys 1691.65 (-1.79%)
ITC 224.00 (-3.16%)
JSW Steel 628.65 (-7.67%)
Kotak Mah. Bank 1964.30 (-3.48%)
Larsen & Toubro 1778.15 (-3.88%)
M & M 853.75 (-4.20%)
Maruti Suzuki 7170.50 (-5.31%)
Nestle India 19222.25 (0.23%)
NTPC 128.85 (-4.70%)
O N G C 147.10 (-5.16%)
Power Grid Corpn 202.00 (-1.10%)
Reliance Industr 2412.60 (-3.22%)
SBI Life Insuran 1130.35 (-2.51%)
Shree Cement 25945.80 (-2.72%)
St Bk of India 470.50 (-4.09%)
Sun Pharma.Inds. 767.30 (-1.99%)
Tata Consumer 766.70 (-5.09%)
Tata Motors 460.20 (-6.61%)
Tata Steel 1112.30 (-5.23%)
TCS 3446.85 (0.03%)
Tech Mahindra 1527.40 (-2.05%)
Titan Company 2292.30 (-4.40%)
UltraTech Cem. 7394.75 (-2.81%)
UPL 703.80 (-3.23%)
Wipro 621.45 (-2.40%)

Jio stake and value unlocking makes Mukesh Ambani the richest businessman in Asia.

Jio stake and value unlocking makes Mukesh Ambani the richest businessman in Asia.
by 5paisa Research Team 20/10/2021

On average, daily wealth creation velocity since 2020 is Rs 163 crore which made him around Rs 60,000 crore in the last year, a rise of 9%.

Mukesh Ambani continues to be the richest man in India for the 10th consecutive year with a wealth of Rs 7,18,000 crore. On average, his daily wealth creation velocity since 2020 is Rs 163 crore which made him around Rs 60,000 crore in the last year, a rise of 9%.

Majority of his wealth is driven by Reliance Industries, Ambani’s family have about 50% shareholding in the company. Reliance Industries became the first Indian company to cross the USD 200 billion (Rs 15 lakh crore) market cap driven by retail and telecom operations. The share price has increased from Rs 1,987 to Rs 2,698 in 2021 which is 35% up YTD.

Turnaround in Reliance Industries business.

Till 2016, the company has been sticking with a traditional oil refinery, petrochemical business, and retail to some extent. Looking at the smartphone usage and requirement of mobile data, Ambani re-entered the telecom business, he provided data, unlimited calls at a much cheaper rate. Within a launch year, Jio got five crore subscribers, and now they have the largest market share in terms of subscribers.

Ambani was able to understand the telecom market potential much earlier. In 2010, he bought a 96% stake in Infotel who was the successful bidder in all 22 circles of the auction for broadband wireless access.

With this turnaround in the business, the company can make collaboration with big tech giants like Facebook. Ambani outlined JioMart which is Jio’s new digital commerce platform and WhatsApp together will enable about three crore small Indian grocery stores to do digital transactions. These shopkeepers will be able to do digital transactions with their customers. This means that you will be able to order and deliver daily items from all the local shops.

Within 5 years, his wealth has grown five times. In the 2016 Forbes list, his net worth was Rs 1,45,000 crore and now it is 7,18,000 crore. His plans are focused on transforming its legacy power business with a push into green energy, committing more than USD 10 billion over three years.

From time-to-time business keeps on changing, but his leadership on the wealthy list remains the same!

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Trending stocks: Keep a close eye on these small-cap stocks for 21 October 2021.

Trending stocks: Keep a close eye on these small-cap stocks for 21 October 2021.
by 5paisa Research Team 20/10/2021

Nifty Bank index ended the session on a flat note, marginally down by 0.06%. Metal stocks witnessed selling pressure and lost shine.

Frontline indices Nifty 50 and Sensex on Wednesday, ended in the red territory down by more than 0.70% each. Nifty Bank index ended the session on a flat note, marginally down by 0.06%. Metal stocks witnessed selling pressure and lost shine. BSE Small-cap index closed at 28,878.73 recording losses of 2.31%.

Keep a close eye on these trending small-cap stocks for Thursday, 21 October 2021:

Tata Teleservices (Maharashtra) – The company has recently announced the launch of ‘Smart Internet’, the industry’s first smart internet leased- single suite combining high-speed internet with cloud-based security and greater control at an optimized cost. Due to the increased frequency and sophistication of cyber-attacks like phishing, ransomware among others, network manageability and visibility has always been a concern that has rendered many businesses unproductive with a profound impact on their financials, reputation, and sustainability. Smart Internet helps overcome all these challenges.

It is clear that as businesses are rapidly digitalizing, they are becoming an easy target for cyber-attacks. They need to invest in reliable security solutions to safeguard their vital digital infrastructure. Security, ultra-fast and reliable connectivity, visibility and manageability are the key attributes of the Smart Internet solution. 

BL Kashyap and Sons – The company has announced that it has been awarded a new project for civil work of commercial space at Gurugram worth Rs 62.15 crore. Their order book during FY 2021-22 stands at Rs 756.02 crore. As the industry continues to get back on its feet, BL Kashyap and Sons Limited looks forward to building more structures that will add more value by defining technological innovations and implementing contemporary construction methods.

With specialization in integrated Engineering, Procurement and Construction (EPC) services for civil construction and infrastructure sector projects, the company has become synonymous with innovation, quality and timeline delivery over the years.

52-week High Stocks - The following small-cap stocks have made fresh 52-week high today – Jyoti Structures, Monte Carlo Fashions, Archidply Décor, TCNS Clothing, Pokarna Limited and Sasken Technologies. Keep a close eye on these counters on Thursday, 21 October 2021.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

These stocks are likely to be in focus on October 21.

These stocks are likely to be in focus on October 21.
by 5paisa Research Team 20/10/2021

Benchmark indices ended in red for the second consecutive session on October 20 amid selling witnessed across the sectors.

At close, the Sensex was down 456.09 points or 0.74% at 61,259.96 level, and the Nifty lowered 152.20 points or 0.83% settling at 18,266.60 level. Bharti Airtel, SBI, IndusInd Bank and Bajaj Finance were the top Sensex gainers whereas Titan Company, HUL, NTPC and Larsen and Toubro were the top Sensex losers.

On Wednesday, about 877 shares have advanced, 2351 shares declined, and 115 shares are unchanged. All the sectoral indices settled in red and in the broader markets, BSE midcap and smallcap indices lost 2% each.

Watch out for these stocks in Thursday’s trading session:

Mindtree – The company has been selected as a strategic partner by Western Asset, one of the world’s leading active fixed-income investment managers, to help drive innovation and differentiated experiences for the company’s global investors. The initial partnership will be for the Western Asset team on their IT infrastructure and application portfolio, while also enabling several strategic business initiatives.

Jubilant FoodWorks – The company declared its results for Q2FY22 which revealed that the net profit rose 58% recording at Rs 121.52 crore versus Rs 76.9 crore reported in Q2FY21. Revenue zoomed 36.6% at Rs 1,101 crore as compared to Rs 805.5 crore on a YoY basis. Whereas on a YoY basis, earnings before interest, tax, depreciation and amortization (EBITDA) stood 33.2% higher at Rs 286 crore in comparison with Rs 214.6 crore.

52-week high stocks – Amid the downside experienced in the markets on Wednesday, the stocks of ICICI Bank, Infosys, SBI and Tech Mahindra in the Sensex pack outperformed the index and made fresh 52-week highs. These stocks are likely to be on the watchlist for Thursday's trading session.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Closing Bell: Market extends losses, Sensex falls by 456 points, Nifty slips below 18300.

Closing Bell: Market extends losses, Sensex falls by 456 points, Nifty slips below 18300.
by 5paisa Research Team 20/10/2021

Equity indices plunged into the red on October 21, 2021, in a highly volatile and profit-booking trading session.


Domestic equity benchmarks Sensex and Nifty50 gave up the initial gains in a volatile trading session on Wednesday. Losses witnessed in oil and gas, financial services, metals and consumer goods pulled the market lower. Broader markets were also volatile and slipped deep into the red. BSE Smallcap index closed at 28,878.73 recording losses of 2.31%.

At the closing bell on Wednesday, the Sensex closed down by 456.09 points or 0.74% at 61,259.96, and the Nifty ended lower by 152.20 points or 0.83% at 18,266.60. Today, 877 shares advanced, 2351 shares declined, and 115 shares were unchanged.

Among the top gainers today were, Bharti Airtel, SBI, Axis Bank, Bajaj Finance, Tech Mahindra and ICICI Bank. While the top losers of the day were Titan Company, HUL, BPCL and Bajaj Finserv.

All the sectoral indices ended in red, with BSE midcap and smallcap losing 2% each.

According to market experts, investors are booking profits at every peak, adding volatility to the market. They also view that investors were awaiting corporate views during September-quarter earnings as higher commodity costs and raw material expenses are expected to hurt margins for companies even as they post profit increases. The market has given us many instances in the recent past where it has been a very promising buy on dips strategy that works.

Consumer giant Hindustan Unilever went down by almost 2.5% to Rs 2,484 after it warned that margins could remain under pressure in the near term due to elevated commodity prices.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Peaks and valleys in the pharma industry-Dr.Reddy’s share rises

by 5paisa Research Team 20/10/2021

Dr. Reddy's Vascepa share gains resume
Dr. Reddy's gVascepa Rx was up 34% monthly and the market share reached 5.5%. Hikma's Rx was up by 2% and the market share touched 14%, during the last 4 months. Vascepa's share came down to 80%, the lowest till date, per the latest weekly data. Dr. Reddy increases Suboxone share: Dr. Reddy's market share in the Suboxone market had remained stable for over a year and it started to move up in July-2021.Dr. Reddy's market share reached 19.8%.

Lupin’s rise in Albuterol HFA market. 
Lupin gains 67bps in Albuterol HFA. Lupin's Albuterol HFA Rx was up 5% last month with a stable total market Rx. Lupin rose by 14.7% which is a 67bps increase. Cipla lost 25bps share. Cipla's market share loss is for the first time since the product was launched. This may indicate that the stock is nearing its peak. Lupin shoots down by 320bps in market share in Famotidine oral solution market; the market share loss was at the slowest since the competitors launched products in May. Lupin's market share stands at 74.8%. 

Semglee market share gains move up by 2%
Seamless (Biocon's Insulin Glargine) Rx was up by 2% and market share remained steady at 4%. 
Updates on other Biosimilars
Biocon's Pegfilgrastim Rx was up by 13% m/m and resulted in 93bps of market share gains however Trastuzumab Rx decreased by 18% and reduced by 185bps share. Alembic loses share in Olmesartan, gains in Valsartan Alembic's Olmesartan Rx was down 13% and reached a market share of 10.2% (down 151bps), while Valsaratan Rx was up 3% with a market share of 20.3% (+44bps). The albuterol market seems to be stabilizing. Sun's Absorica generic Rx was up 10% YoY. Sublocade Rx trend continues to move up. Dr. Reddy's Suboxone share moved up in recent weeks. Sublocade prescriptions have gradually moved up in the last few months. Alvogen lost some Suboxone market share to Dr. Reddy's in recent weeks. The latest weekly data shows Vascepa's market share at 80%.Dr. Reddy's gVascepa share gains 142bps share. Lupin continues to lose share in Famotidine but gradually. Alembic lost 151bps share in Olmesartan during last. Alembic saw a slight market share uptick in Valsartan. The Mesalamine 1.2gm market was quite stable. The Mesalamine 1.2gm market was stable. The dry-eye market was unchanged.Ilumya Rx was down by 3% m/m.Cipla's Cinacalcet Rx was steady vs the previous month. Solos prescriptions were up 6% m/m. Biocon's Semglee market share gains have stalled in the last few weeks. Biocon's Pegfilgrastim Rx up 13% m/m.Amgen lost Pegfilgrastim share to peers in the last month.Biocon Trastuzumab Rx down 18% m/m.Biocon-Viatris's Trastuzumab Rx share falls to 15.3% from 17.2%. Biocon-Viatris's market share (for August) by IQVIA sales is 5.9% in Trastuzumab. Lupin's Glumetza share is largely stable.
 

Peaks and valleys in the pharma industry-Dr.Reddy’s share rises
Dr. Reddy's Vascepa share gains resume
Dr. Reddy's gVascepa Rx was up 34% monthly and the market share reached 5.5%. Hikma's Rx was up by 2% and the market share touched 14%, during the last 4 months. Vascepa's share came down to 80%, the lowest till date, per the latest weekly data. Dr. Reddy increases Suboxone share: Dr. Reddy's market share in the Suboxone market had remained stable for over a year and it started to move up in July-2021.Dr. Reddy's market share reached 19.8%.

Lupin’s rise in Albuterol HFA market. 
Lupin gains 67bps in Albuterol HFA. Lupin's Albuterol HFA Rx was up 5% last month with a stable total market Rx. Lupin rose by 14.7% which is a 67bps increase. Cipla lost 25bps share. Cipla's market share loss is for the first time since the product was launched. This may indicate that the stock is nearing its peak. Lupin shoots down by 320bps in market share in Famotidine oral solution market; the market share loss was at the slowest since the competitors launched products in May. Lupin's market share stands at 74.8%. 

Semglee market share gains move up by 2%
Seamless (Biocon's Insulin Glargine) Rx was up by 2% and market share remained steady at 4%. 
Updates on other Biosimilars
Biocon's Pegfilgrastim Rx was up by 13% m/m and resulted in 93bps of market share gains however Trastuzumab Rx decreased by 18% and reduced by 185bps share. 
Alembic loses share in Olmesartan, gains in Valsartan 
Alembic's Olmesartan Rx was down 13% and reached a market share of 10.2% (down 151bps), while Valsaratan Rx was up 3% with a market share of 20.3% (+44bps). 
The albuterol market seems to be stabilizing. Sun's Absorica generic Rx was up 10% YoY. Sublocade Rx trend continues to move up. Dr. Reddy's Suboxone share moved up in recent weeks. Sublocade prescriptions have gradually moved up in the last few months. Alvogen lost some Suboxone market share to Dr. Reddy's in recent weeks. The latest weekly data shows Vascepa's market share at 80%.Dr. Reddy's gVascepa share gains 142bps share. Lupin continues to lose share in Famotidine but gradually. Alembic lost 151bps share in Olmesartan during last. Alembic saw a slight market share uptick in Valsartan. The Mesalamine 1.2gm market was quite stable. The Mesalamine 1.2gm market was stable. The dry-eye market was unchanged.Ilumya Rx was down by 3% m/m.Cipla's Cinacalcet Rx was steady vs the previous month. Solos prescriptions were up 6% m/m. Biocon's Semglee market share gains have stalled in the last few weeks. Biocon's Pegfilgrastim Rx up 13% m/m.Amgen lost Pegfilgrastim share to peers in the last month.Biocon Trastuzumab Rx down 18% m/m.Biocon-Viatris's Trastuzumab Rx share falls to 15.3% from 17.2%. Biocon-Viatris's market share (for August) by IQVIA sales is 5.9% in Trastuzumab. Lupin's Glumetza share is largely stable.
 

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Jindal Stainless (Hisar) commissions Phase I of brown-field expansion at speciality products division.

Jindal Stainless (Hisar) commissions Phase I of brown-field expansion at speciality products division.
by 5paisa Research Team 20/10/2021

This capacity expansion takes the total precision strip production capacity to 48,000 TPA from the existing 22,000 TPA.

Jindal Stainless (Hisar) has announced that it has commissioned 26,000 tons per annum (TPA) capacity Precision Strip Mill as part of the first phase of its latest brown-field expansion plan at its Specialty Products Division (SPD).

The capacity expansion of precision strips will further strengthen the company’s presence in segments like auto, process industry, and oil and petrochemical. It will also be augmenting supplies to aerospace and electric vehicles. This capacity expansion takes the total precision strip production capacity to 48,000 TPA from the existing 22,000 TPA. 

The total capital expenditure for the brownfield expansion is estimated at Rs 450 crore over the next two years. As part of the expansion, the company plans to increase its total precision strip capacity to 60,000 tons per annum by the end of Q2FY23 with an estimated capital expenditure of Rs 250 crore.

The capacity expansion at SPD is part of the company’s plan to leverage its leadership position in speciality and value-added products. After this expansion, the operational capability will expand and products up to 650 mm width would be manufactured. This expansion will further help the company consolidate its leadership position in the international markets as well.

Managing Director of Jindal Stainless (Hisar), Abhyuday Jindal stated in a filing with the exchange, “The latest capacity addition to JSHL’s Specialty Products Division portfolio will strengthen our product mix in the value-added segment and double our share in the global production to 8%. The capacity enhancement is expected to boost JSHL’s revenues by 8-10%.” 

Jindal Stainless (Hisar) is an integrated stainless-steel manufacturer with facilities starting from melting, casting, and hot rolling to cold rolling and other value additions. It has a melting capacity of 800,000 TPA. The company’s Specialty Product Division (SPD) caters to the high-end precision and speciality stainless steel requirements of reputed Indian and international customers. This division serves the niche requirements in thinner sections for specific applications in various stainless-steel grades.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order